Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment | Zendy

Eeva Sliz | Zendy; Johannes Kettunen | Zendy; Michael V. Holmes | Zendy; Clare Oliver Williams | Zendy; Charles Boachie | Zendy; Qin Wang | Zendy; Minna Männikkö | Zendy; Sylvain Sebért | Zendy; Robin Walters | Zendy; Kuang Lin | Zendy; Iona Y. Millwood | Zendy; Robert B. Clarke | Zendy; Liming Li | Zendy; Naomi Rankin | Zendy; Paul Welsh | Zendy; Christian Delles | Zendy; J. Wouter Jukema | Zendy; Stella Trompet | Zendy; Ian Ford | Zendy; Markus Perola | Zendy; Veikko Salomaa | Zendy; MarjoRiitta Järvelin | Zendy; Zhengming Chen | Zendy; Debbie A. Lawlor | Zendy; Mika AlaKorpela | Zendy; John Danesh | Zendy; George Davey Smith | Zendy; Naveed Sattar | Zendy; Adam S. Butterworth | Zendy; Peter Würtz | Zendy

AI Assistant Blog Pricing

Open Access

Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment

Author(s) -

Eeva Sliz,

Johannes Kettunen,

Michael V. Holmes,

Clare Oliver Williams,

Charles Boachie,

Qin Wang,

Minna Männikkö,

Sylvain Sebért,

Robin Walters,

Kuang Lin,

Iona Y. Millwood,

Robert B. Clarke,

Liming Li,

Naomi Rankin,

Paul Welsh,

Christian Delles,

J. Wouter Jukema,

Stella Trompet,

Ian Ford,

Markus Perola,

Veikko Salomaa,

MarjoRiitta Järvelin,

Zhengming Chen,

Debbie A. Lawlor,

Mika AlaKorpela,

John Danesh,

George Davey Smith,

Naveed Sattar,

Adam S. Butterworth,

Peter Würtz

Publication year - 2018

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.118.034942

Subject(s) - pcsk9 , statin , medicine , lipoprotein , cholesterol , kexin , endocrinology , population , rosuvastatin , pharmacology , ldl receptor , environmental health

Both statins and PCSK9 inhibitors lower blood low-density lipoprotein cholesterol (LDL-C) levels to reduce risk of cardiovascular events. To assess potential differences between metabolic effects of these two lipid-lowering therapies, we performed detailed lipid and metabolite profiling of a large randomized statin trial and compared the results with the effects of genetic inhibition of PCSK9, acting as a naturally occurring trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog